3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
3
Thoracic
2
Breast
2
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
2
Brain Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Interventions
Radiosurgery
27
Radiotherapy
17
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
Bevacizumab
13
Pemetrexed
10
Carboplatin
10
pembrolizumab
9
Gefitinib
9
osimertinib
8
icotinib
7
Temozolomide
7
Nivolumab
6
Specimen Handling
5
Paclitaxel
5
Spermine Synthase
4
Mental Status and Dementia Tests
4
Ipilimumab
4
Drug Therapy
4
Cisplatin
4
atezolizumab
3
alectinib
3
aflutinib
3
Radiation
3
Immunotherapy
3
Fluorodeoxyglucose F18
3
regorafenib
2
paclitaxel-Angiopep-2 conjugate
2
motexafin gadolinium
2
epothilone B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
cabazitaxel
×
Thoracic
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled
NCT01913067
2014-07-24
CRANIAL
Jules Bordet Institute
Phase 2
Withdrawn